- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07382739
Une étude de phase 2 sur la préparation immunitaire induite par radiothérapie pour améliorer l'elranatamab (Elra) dans le myélome multiple réfractaire en rechute (RRMM) avec maladie extramédullaire (EMD) et maladie paramédullaire (PMD) "PRIME-EMD-PMD"
Une étude de phase 2 sur la préparation immunitaire induite par la radiothérapie pour améliorer l'elranatamab (Elra) dans le myélome multiple réfractaire en rechute (RRMM) avec maladie extramédullaire (EMD) et maladie paramédullaire (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Primary Objectives To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate (ORR) at 3 months
Secondary Objectives To describe adverse events (AEs). To determine time to next treatment (TTNT). To evaluate progression-free survival (PFS). To determine overall survival (OS). To estimate quality of life (QOL). To assess local control to the irradiated lesions To determine differences in response in patients with EMD vs PMD To determine differences in response in patients High Risk (HR) vs Standard Risk (SR) disease
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Christine Ye, MD
- Numéro de téléphone: 832-748-6369
- E-mail: jcye@mdanderson.org
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
Chercheur principal:
- Christine Ye, MD
-
Contact:
- Christine Ye, MD
- Numéro de téléphone: 832-748-6369
- E-mail: jcye@mdanderson.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
-
RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:
- Relapsed disease: progressive disease (PD) >60 days after cessation of prior therapy
- Refractory disease: PD <=60 days after cessation of prior therapy, <25% reduction in paraprotein (monoclonal protein [M-protein] or serum free light chains [sFLC]) or measurements of EMD/PMD
-
Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria
-
At least one locus of EMD or PMD present on imaging (either PET/CT or magnetic resonance imaging [MRI]):
-
EMD: extramedullary plasmacytoma, not a contiguous extension from a bone lesion.
-
PMD: paraskeletal plasmacytoma, contiguous extension from a bone lesion At least one locus of EMD/PMD that was not previously radiated and can be treated with radiation
-
Hematology (supportive care is allowed, including transfusions and granulocyte colony stimulating factor (G-CSF), if cytopenia is deemed secondary to myeloma disease burden):
-
Hemoglobin (Hgb) >=7g/dL
-
Platelet>=50K/uL
-
Absolute neutrophil count (ANC) >=0.75K/uL
-
Chemistry:
-
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) <=2.5 x upper
-
limit of normal (ULN)
-
Total bilirubin (TBili) <=1.5ULN (except for a known history of Gilbert syndrome)
-
Creatinine clearance (CrCL) >=30mL/min/1.73m2
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) <=2, unless ECOG PS due to pain/morbidity secondary to underlying myeloma disease, with the potential of improved ECOG PS to <=2.
-
All participants must be either
-
Not of childbearing potential, or
-
Practicing at least 1 highly effective method of contraception until 6 months after the last dose of study treatment.
-
Childbearing age female participantsmust have a negative serum pregnancy test at screening and must agree to further pregnancy tests during the study.
Exclusion Criteria
-
Prior or concurrent exposure to any of the following in the specified time frame prior to the first dose of Elra treatment:
- Within 14 days or at least 5 half-lives, whichever is less, of any investigational treatment
- Within 7 days of IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies
- Within 12 weeks of autologous stem-cell therapy (ASCT) or 6 months of AlloSCT and has to be off immunosuppressive agents >=42 days without signs of graft versus host disease (GVHD)
- Within 2 weeks of major surgery
- Within 6 months of cerebrovascular accident (CVA) events
-
Waldenstrom, POEMS, Amyloidosis, ongoing plasma cell leukemia (PCL)
-
History of Human Immunodeficiency Virus (HIV)
-
Active, uncontrolled HBV infection despite antiviral therapy.
-
Uncontrolled cardiac, pulmonary, gastrointestinal (GI), hepatic, renal, central nervous system(CNS) diseases not due to myeloma, at the discretion of investigator, that are not a candidate for T cell engager (TCE) therapy
-
Uncontrolled or recurrent infections
-
Autoimmune disease requiring systemic treatment (except for low dose steroids, equivalent to 10mg/day or less of prednisone)
-
Disabling psychiatric conditions, substance abuse (alcohol, or drug), dementia, altered mental status
-
Any other active malignancies within 5 years of completing treatment (with the exception of hormonal therapies for breast or prostate cancer) and >minimal risk of recurrence
-
Myelodysplastic syndromes (MDS)
-
Any issues that may impair the ability of the participant to receive or tolerate the planned treatment, to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that would prevent, limit, or confound the protocol specified assessments.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Elra or other agents used in study.
-
History or possible non-compliance with recommended treatments
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment with Elranatamab (SubQ) Q4W
To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate |
Given by IV |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and adverse events (AEs)
Délai: Through study completion; an average of 1 year
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Christine Ye, MD, M.D. Anderson Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Tumeurs, plasmocyte
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Troubles hémorragiques
- Maladies hémiques et lymphatiques
- Myélome multiple
Autres numéros d'identification d'étude
- 2025-1557
- NCI-2026-00668 (Autre identifiant: NCI-CTRP Clinical Registry)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .